Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

21. Mai 2024 20:05 ET | Quelle: Robbins LLP

June 4th Lead Plaintiff Deadline Approaching in Class Action Against Checkpoint Therapeutics, Inc. – Contact Robbins LLP Today

Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab
26. April 2024 16:56 ET | Quelle: Robbins LLP

Robbins LLP Reminds Stockholders of CKPT to Contact the Law Firm for Information About the Checkpoint Therapeutics, Inc. Class Action Lawsuit

Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab
15. April 2024 17:14 ET | Quelle: Robbins LLP

CKPT Class Action Alert: Robbins LLP Reminds Stockholders of Checkpoint Therapeutics, Inc. Class Action

Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab
10. April 2024 17:52 ET | Quelle: Portnoy Law

Checkpoint Therapeutics, Inc. investors: Please contact the Portnoy Law Firm to recover your losses; June 4, 2024 deadline.

Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, April 10, 2024 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Checkpoint Therapeutics, Inc....
07. April 2024 23:21 ET | Quelle: Robbins LLP

Investor Notice: Robbins LLP Informs Investors of Class Action Filed Against Checkpoint Therapeutics, Inc. (CKPT)

Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab